2 results
Approved WMOCompleted
Cohort 1 (HER2-positive/amplified MBC): MCLA-128 + trastuzumab ± vinorelbine Primary objective:• Evaluate efficacy of MCLA-128 combined with trastuzumab ± vinorelbine in terms of clinical benefit rate (CBR) at 24 weeks based on RECIST 1.1 (per…
Approved WMORecruiting
The primary objective of this study is to evaluate the effect of FES on participation level: achieving of individual goals, using the goal attainment scale (GAS)), and the Canadian Occupational Performance Measure (COPM) for the long term. Secondary…